cytarabine has been researched along with Diabetes Insipidus, Neurogenic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagihara, K; Hino, M; Inaba, A; Koh, H; Nagata, Y; Nakamae, H; Nakane, T; Nakao, Y; Nanno, S; Nishimoto, M; Okamura, H; Sakabe, M; Shimono, T | 1 |
| Hazeki, D; Imamura, M; Kawakami, K; Kawano, Y; Nakagawa, S; Okamoto, Y; Shinkoda, Y | 1 |
2 other study(ies) available for cytarabine and Diabetes Insipidus, Neurogenic
| Article | Year |
|---|---|
[Acute myeloid leukemia with monosomy 7 and inv(3)(q21q26.2) complicated with central diabetes insipidus].
Topics: Chromosome Deletion; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 7; Cytarabine; Diabetes Insipidus, Neurogenic; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; Treatment Outcome; Young Adult | 2013 |
Central diabetes insipidus as a very late relapse limited to the pituitary stalk in Langerhans cell histiocytosis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Diabetes Insipidus, Neurogenic; Female; Histiocytosis, Langerhans-Cell; Humans; Japan; Magnetic Resonance Imaging; Organ Size; Pituitary Gland; Recurrence; Treatment Outcome | 2016 |